Q-omics provides the consensus-scored LRCH2 profile across patient tissues and cancer cell-line models. LRCH2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LRCH2 is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, LRCH2 RNA expression shows 23,617 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRP, LUAD, and CCRCC as cancer lineages where LRCH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRCH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRCH2 survival associations across molecular data types. LRCH2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRCH2 RNA expression–survival associations across cancer types. High LRCH2 expression shows unfavorable associations in KIRP, STAD, LUSC and UCEC, but favorable associations in UCS and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LRCH2 RNA expression.
This table summarizes LRCH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LRCH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRCH2 shows lower tumor expression in LUAD, BLCA, COAD, LUSC, UCEC and BRCA. The LUAD box plot shows higher LRCH2 RNA expression in normal versus tumor tissue (log2 FC = −1.556, t-test p < 0.001).
This table shows molecular features associated with LRCH2 in patient tissues and cancer cell lines. In patient samples, LRCH2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRCH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BREAST.
